IAG Launches DYNAMIKA 7: A Game-Changer in Imaging Clinical Trials

DYNAMIKA V7 has achieved the British Standards Institute (BSI) surveillance audit certification following a recent SOC II Type I compliance certification. DYNAMIKA was recently named an Award Category Winner for Innovation in the 2024 Pharmaceutical Technology Excellence Awards, recognizing the platform’s proprietary technology and its potential for driving change in the pharmaceutical industry.

As clinical trials become increasingly complex, imaging plays a pivotal role in demonstrating treatment efficacy and expediting regulatory approvals. DYNAMIKA 7 has been designed to meet the evolving needs of biotech and pharma partners by providing unmatched precision, speed, and agility in image data analysis.

“With DYNAMIKA 7, we are empowering our partners to reimagine what’s possible in imaging clinical trials. The platform is more than a technology—it’s a strategic enabler that reduces uncertainty, accelerates timelines, and brings clarity to complex data. This release reflects our commitment to innovation, collaboration, and the ultimate goal of delivering life-changing therapies to patients faster,” said Olga Kubassova, CEO and founder of Image Analysis Group.

Key highlights of DYNAMIKA 7 include:

• Next-generation analytics powered by advanced AI algorithms, delivering deeper insights into disease progression and treatment response.
• Enhanced scalability and performance, enabling robust data logistics of large datasets in global, multi-center trials.
• Streamlined regulatory compliance, with new reporting capabilities, the data generated in trials supports FDA, EMA, and global submissions.
• User-centered design, offering an intuitive interface for clinical teams to review, collaborate, and make data-driven decisions quickly.

AI in DYNAMIKA

With artificial intelligence becoming an essential driver of business success, IAG aims to bridge the gap between innovation and usability of clinical trial imaging platforms. Designed for a variety of trial scenarios such as collect and hold, umbrealla and basket trials, RWE, and more, DYNAMIKA platform delivers scalable infrastructure and relibale data workflows that redefine efficiency.

The launch of DYNAMIKA 7 and IAG’s Partnerships network marks just the beginning of an exciting journey. IAG team is committed to continuous innovation, with new features and capabilities in the technical pipeline, driven by customer feedback and emerging industry trends.

“We are not just introducing another tool—we are shaping the future of clinical trial imaging,” Jon Himoff added. “IAG empowers companies to work smarter, adapt faster, and achieve success beyond expectations.”

About Image Analysis Group (IAG)

Image Analysis Group is a science-driven partner to biotech and pharma companies, specializing in the use of innovative imaging, AI, and advanced analytics to transform clinical development. With a unique combination of deep therapeutic expertise and cutting-edge technology, IAG helps sponsors de-risk drug development, accelerate clinical timelines, and deliver meaningful outcomes for patients.